Why the study?
To revisit the year's developments in percutaneous coronary intervention, structural heart interventions, and adjunctive pharmacotherapy amidst the COVID-19 pandemic.
A yearly review summarizing the 2021 developments in percutaneous coronary intervention, structural heart interventions, and adjunctive pharmacotherapy.
Since last year's report in the European Heart Journal, we have witnessed substantial progress in all aspects of interventional cardiology. Of note, the practice of interventional cardiology took place amidst successive waves of the COVID-19 pandemic, which continues to be a major burden for all healthcare professionals around the globe. In our yearly review, we shall revisit the developments in percutaneous coronary intervention (PCI), structural heart interventions, and adjunctive pharmacotherapy.
No takes yet. Share an insight, caveat, or question.
Escaned et al. (2021) conducted a review in Interventional cardiology.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: